Announced details
Number of clinics introducing Dr.Supporter: more than 2,000 cumulatively since sales began in July 2021
Founding member of the General Incorporated Association NO Health Innovation Council. 株式会社テイコク製薬社 developed IFMC. and processes and uses it in Dr.Supporter.
Head office: Minato Ward, Osaka; Representative Director and President: Hatakeyama Shinnosuke (畠山進之介). Other attributes: Not disclosed.
Osaka (principal office of the General Incorporated Association NO Health Innovation Council)
The company states that it will strengthen and expand its business in the preventive medicine and medical-device fields and work to increase corporate value on a sustained basis. The specific amount of the impact on results is Not disclosed.
The company does not address Contract Value / Offering price.
Ministry of Health, Labour and Welfare
| Item | Details |
|---|---|
| Names of Products / Services Covered | Dr.Supporter (ドクターサポーター), IFMC. (イフミック), Home-use nitric oxide (NO)-producing blood circulation promotion device |
| Counterparty | 株式会社テイコク製薬社 |
| Counterparty overview | Head office: Minato Ward, Osaka; Representative Director and President: Hatakeyama Shinnosuke (畠山進之介). Other attributes: Not disclosed. |
| Relationship with the Company | Founding member of the General Incorporated Association NO Health Innovation Council. 株式会社テイコク製薬社 developed IFMC. and processes and uses it in Dr.Supporter. |
| Launch date | July 2021 (launch of Dr.Supporter sales; track record) |
| Applicable area | Preventive medicine, Medical devices, Healthcare, Exercise, Sleep, Daily conditioning |
| Location | Osaka (principal office of the General Incorporated Association NO Health Innovation Council) |
| Usage history | Number of clinics introducing Dr.Supporter: more than 2,000 cumulatively since sales began in July 2021 |
| Impact on Business Performance | The company states that it will strengthen and expand its business in the preventive medicine and medical-device fields and work to increase corporate value on a sustained basis. The specific amount of the impact on results is Not disclosed. |
| Source | Ministry of Health, Labour and Welfare |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To develop the industrial infrastructure for scientific evidence, evaluation methods, safety, and appropriate labeling related to nitric oxide (NO) technologies, thereby contributing to longer healthy lifespans and the sound development of related industries. In addition, following the establishment of the general medical-device generic name “home-use nitric oxide (NO)-producing blood circulation promotion device,” the association will enter this field by leveraging its track record in developing existing brands and its network of bone-setting clinics.